Cambridge Investment Research Advisors
RDHL

Cambridge Investment Research Advisors’s Redhill Biopharma RDHL Stock Holding History

Cambridge Investment Research Advisors’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-26
Closed -$65K – 3179
2022
Q1 		$65K Sell
26
-2
-7% -$4.74K ﹤0.01% 3062
2021
Q4 		$71K Buy
+28
New +$112K ﹤0.01% 3068

Other funds holding RDHL

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Cambridge Investment Research Advisors's RDHL Position: Q2 2022 in Review

Cambridge Investment Research Advisors sold out of Redhill Biopharma (RDHL) in Q2 2022, closing a stake of 26 shares — an estimated $65K sold.

Cambridge Investment Research Advisors first reported a position in RDHL in Q4 2021 and held it in 2 quarters. The position peaked at $71K in Q4 2021. 44 funds tracked by Wall St. Rank hold RDHL as of Q2 2022.

  • Cambridge Investment Research Advisors reported no remaining Redhill Biopharma position as of Q2 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 26 Redhill Biopharma shares in Q2 2022, an estimated $65K.
  • Cambridge Investment Research Advisors first reported a position in Redhill Biopharma in Q4 2021 and held it in 2 quarters.
  • Cambridge Investment Research Advisors's Redhill Biopharma position peaked at $71K in Q4 2021.
  • 44 funds tracked by Wall St. Rank held Redhill Biopharma as of Q2 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2022, filed 13 Jul 2022.